Bisphosphonate related osteonecrosis of the jaws treated by surgical resection and immediate osseous microvascular reconstruction

Journal of Cranio-Maxillofacial Surgery

Volumn 37, Issue 5, 2009, Pages 291-297

  Mücke, Thomas ^a   Haarmann, Stephan ^a   Wolff, Klaus Dietrich ^a   Hölzle, Frank ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

bisphosphonates; bone; fibula flap; iliac crest; jaw; microvascular reconstruction; osteonecrosis; therapy

Indexed keywords

CLINDAMYCIN; ZOLEDRONIC ACID;

ADULT; ANAMNESIS; ARTICLE; BONE REMODELING; BONE RESECTION; BONE SCINTISCANNING; BREAST CANCER; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DEBRIDEMENT; DISEASE COURSE; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; ILIAC CREST; JAW OSTEONECROSIS; MANDIBLE RECONSTRUCTION; METASTASIS; PATIENT SATISFACTION; TISSUE FLAP;

BONE DENSITY CONSERVATION AGENTS; BONE TRANSPLANTATION; DIPHOSPHONATES; FEMALE; HUMANS; MANDIBULAR DISEASES; MIDDLE AGED; NEOPLASM METASTASIS; ORAL SURGICAL PROCEDURES; OSTEONECROSIS; RECONSTRUCTIVE SURGICAL PROCEDURES; SEVERITY OF ILLNESS INDEX; SURGICAL FLAPS; TREATMENT OUTCOME;

EID: 67349160804     PISSN: 10105182     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcms.2008.12.004     Document Type: Article

References (40)

1. AAOMS. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65 (2007) 369
2. Abu-Id M.H., Acil Y., Gottschalk J., and Kreusch T. Bisphosphonate-associated osteonecrosis of the jaw. Mund Kiefer Gesichtschir 10 (2006) 73
3. Badros A., Weikel D., Salama A., Goloubeva O., Schneider A., Rapoport A., Fenton R., Gahres N., Sausville E., Ord R., and Meiller T. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 24 (2006) 945
4. Bagan J.V., Jimenez Y., Murillo J., Hernandez S., Poveda R., Sanchis J.M., Diaz J.M., and Scully C. Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. Oral Oncol 42 (2006) 327
5. Bamias A., Kastritis E., Bamia C., Moulopoulos L.A., Melakopoulos I., Bozas G., Koutsoukou V., Gika D., Anagnostopoulos A., Papadimitriou C., Terpos E., and Dimopoulos M.A. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23 (2005) 8580
6. Berenson J.R. Advances in the biology and treatment of myeloma bone disease. Semin Oncol 29 (2002) 11
7. Berenson J.R., Lichtenstein A., Porter L., Dimopoulos M.A., Bordoni R., George S., Lipton A., Keller A., Ballester O., Kovacs M., Blacklock H., Bell R., Simeone J.F., Reitsma D.J., Heffernan M., Seaman J., and Knight R.D. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 16 (1998) 593
8. Berenson J.R., Lichtenstein A., Porter L., Dimopoulos M.A., Bordoni R., George S., Lipton A., Keller A., Ballester O., Kovacs M.J., Blacklock H.A., Bell R., Simeone J., Reitsma D.J., Heffernan M., Seaman J., and Knight R.D. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 334 (1996) 488
9. Body J.J. Breast cancer: bisphosphonate therapy for metastatic bone disease. Clin Cancer Res 12 (2006) 6258s
10. Boonyapakorn T., Schirmer I., Reichart P.A., Sturm I., and Massenkeil G. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol (2008)
11. Chuah C., Barnes D.J., Kwok M., Corbin A., Deininger M.W., Druker B.J., and Melo J.V. Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells. Leukemia 19 (2005) 1896
12. Conte P.F., Giannessi P.G., Latreille J., Mauriac L., Koliren L., Calabresi F., and Ford J.M. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomized, multicenter phase III trial. Ann Oncol 5 Suppl 7 (1994) S41
13. Demerjian N., Bolla G., and Spreux A. Severe oral ulcerations induced by alendronate. Clin Rheumatol 18 (1999) 349
14. Diel I.J., Bergner R., and Grotz K.A. Adverse effects of bisphosphonates: current issues. J Support Oncol 5 (2007) 475
15. Dimopoulos M.A., Kastritis E., Anagnostopoulos A., Melakopoulos I., Gika D., Moulopoulos L.A., Bamia C., Terpos E., Tsionos K., and Bamias A. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 91 (2006) 968
16. Engroff S.L., and Kim D.D. Treating bisphosphonate osteonecrosis of the jaws: is there a role for resection and vascularized reconstruction?. J Oral Maxillofac Surg 65 (2007) 2374
17. Fleisch H. Bisphosphonates in osteoporosis. Eur Spine J 12 Suppl 2 (2003) S142
18. Gonzalez-Moles M.A., and Bagan-Sebastian J.V. Alendronate-related oral mucosa ulcerations. J Oral Pathol Med 29 (2000) 514
19. Green J.R. Bisphosphonates: preclinical review. Oncologist 9 Suppl 4 (2004) 3
20. Green J.R., Seltenmeyer Y., Jaeggi K.A., and Widler L. Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models. Pharmacol Toxicol 80 (1997) 225
21. Greenberg M.S. Intravenous bisphosphonates and osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 98 (2004) 259
22. Hidalgo D.A. Fibula free flap: a new method of mandible reconstruction. Plast Reconstr Surg 84 (1989) 71
23. Hortobagyi G.N., Theriault R.L., Porter L., Blayney D., Lipton A., Sinoff C., Wheeler H., Simeone J.F., Seaman J., and Knight R.D. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 335 (1996) 1785
24. Hughes D.E., MacDonald B.R., Russell R.G., and Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 83 (1989) 1930
25. Hughes D.E., Wright K.R., Uy H.L., Sasaki A., Yoneda T., Roodman G.D., Mundy G.R., and Boyce B.F. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10 (1995) 1478
26. Kildal M., Wei F.C., and Chang Y.M. Free vascularized bone grafts for reconstruction of traumatic bony defects of mandible and maxilla. World J Surg 25 (2001) 1067
27. Lugassy G., Shaham R., Nemets A., Ben-Dor D., and Nahlieli O. Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity. Am J Med 117 (2004) 440
28. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61 (2003) 1115
29. Marx R.E., Cillo Jr. J.E., and Ulloa J.J. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65 (2007) 2397
30. Marx R.E., Sawatari Y., Fortin M., and Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63 (2005) 1567
31. Migliorati C.A. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 21 (2003) 4253
32. Migliorati C.A., Schubert M.M., Peterson D.E., and Seneda L.M. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 104 (2005) 83
33. Milner R.J., Farese J., Henry C.J., Selting K., Fan T.M., and de Lorimier L.P. Bisphosphonates and cancer. J Vet Intern Med 18 (2004) 597
34. Ruggiero S.L., Mehrotra B., Rosenberg T.J., and Engroff S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527
35. Santini D., Vespasiani Gentilucci U., Vincenzi B., Picardi A., Vasaturo F., La Cesa A., Onori N., Scarpa S., and Tonini G. The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 14 (2003) 1468
36. Sietsema W.K., Ebetino F.H., Salvagno A.M., and Bevan J.A. Antiresorptive dose-response relationships across three generations of bisphosphonates. Drugs Exp Clin Res 15 (1989) 389
37. Vasikaran S.D. Bisphosphonates: an overview with special reference to alendronate. Ann Clin Biochem 38 (2001) 608
38. Vogel F., Scholz H., al-Nawas B., Elies W., Kresken M., Lode H., Muller O., Naber K.G., Petersen E., Shah P., Sorgel F., Stille W., Tauchnitz C., Trautmann M., Ullmann U., Wacha H., and Wiedemann B. Rational use of oral antibiotics. Findings of an expert commission of the Paul Ehrlich Society for Chemotherapy. Med Monatsschr Pharm 25 (2002) 193
39. Wellington K., and Goa K.L. Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy. Drugs 63 (2003) 417
40. Wood J., Bonjean K., Ruetz S., Bellahcene A., Devy L., Foidart J.M., Castronovo V., and Green J.R. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302 (2002) 1055